prevention of bacterial & viral cross- nfection in
TRANSCRIPT
![Page 1: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/1.jpg)
PPrevention of revention of BBacterial & acterial & VViral iral CCrossross--IInfection in nfection in DDialysis ialysis UUnitnit
Associate Professor Josephine ChowAssociate Professor Josephine ChowArea Clinical Manager, Cardiovascular StreamCo-Director, Liverpool Renal Research Centre
Sydney South West Area Health Service
School of NursingThe University of Sydney
School of NursingThe University of Tasmania
![Page 2: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/2.jpg)
![Page 3: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/3.jpg)
Area: 7,682,300 sq kmArea: 7,682,300 sq km
Population: 21 millionPopulation: 21 million
Dialysis population: 10,062 patientsDialysis population: 10,062 patients
![Page 4: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/4.jpg)
Sydney South West Sydney South West Area Health ServiceArea Health Service
![Page 5: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/5.jpg)
Sydney South West Area Health ServiceSydney South West Area Health Service
![Page 6: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/6.jpg)
ObjectivesObjectives• To outline the common bacterial & viral infection
amongst the haemodialysis population
• To convey a basic understanding of the common infectious disease processes (i.e. mode of transmission, treatment, etc.)
• Discuss the management on common bacterial & viral infection
• To identify strategies for preventing cross- infection
![Page 7: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/7.jpg)
Common Bacteria and Viruses in Common Bacteria and Viruses in DialysisDialysis• Blood-Borne Viruses (BBV)
– Hepatitis B– Hepatitis C– Human Immunodeficiency Virus
• Multi Resistant Organism (MRO)– Methycillin resistant staphylococcus – Vancomycin resistant enterococcus
![Page 8: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/8.jpg)
Hepatitis B Virus Hepatitis B Virus (HBV)(HBV)• Non-cytopathic virus Transmission • Perinatal transmission (most cases)
• High prevalence amongst endemic countries – China, South East Asia, Pacific nations
• Adults transmission via sexual contact & IV drug use
• Australia HBV carrier (160,000 – 200,000)
• Needle stick injury - Risk of percutaneous exposure, 30% (DNA +ve); 3% (non-DNA +ve)
![Page 9: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/9.jpg)
SIMPLIFIED VACCINATION SIMPLIFIED VACCINATION SCHEMASCHEMA
PATIENT SEROLOGY Action Comments
HEPB sAg +ve HEPB sAb<10
No vaccination DIALYSE IN ISOLATIONMonitor HepB sAg/sAb 6 monthlyRecommend referral to Hepatologist.
HEPB sAg +ve HEPB sAb>10
No vaccination DIALYSE IN ISOLATIONMonitor HepB sAg/sAb 6 monthlyRARE: Probably clearing viral hepatitis infection ! Recommend referral to Hepatologist.
HEPB sAg -ve HEPB sAb<10
NEEDSVACCINATION or BOOSTER
HEP B NON-IMMUNEMonitor HepB sAg/sAb 6 monthly
HEPB sAg -ve HEPB sAb>10
No vaccination HEP B IMMUNEMonitor HepB sAg/sAb 6 monthly
![Page 10: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/10.jpg)
Hep B sAb <10, Hep B sAg –ve
Vaccination x 4 (0, 1, 2, 6 months)
Repeat serology @ end of the course.
Hep B sAb >10 Hep B sAb <10
Repeat serology after 6 months
Give booster vaccinations x 4 over 6 months, second course (0, 1, 2, 6)
Hep B sAb >10Repeat serology in 6 months.
Hep B sAb <10,Pt. does not seroconvert, no more vaccination
Repeat serology every 6 months
Hep B vaccination flow chart Hep B vaccination flow chart
Liverpool HospitalLiverpool Hospital
![Page 11: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/11.jpg)
Summary of Policies (HBV)Summary of Policies (HBV)
![Page 12: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/12.jpg)
Hepatitis C Hepatitis C (HCV)(HCV)• Virus – flavivirus family
• Discovered – infected serum injected to chimpanzees – (non-A, non-B hepatitis) – antibody test
• Transmission – Predominantly parenteral (drug use) – 80%– Immigrant population- poor infection control practices
during procedures (vaccination, European & Asian acquired); chemoprophylaxis program (for schistosomiasis, Egyptian acquired)
– Sexual transmission – (controversial) very low level (higher: if HIV +ve & high HCV viral load; presence of blood in genital tract - menstruation)
– Perinatal transmission – 5% of deliveries (higher if HIV +ve)
![Page 13: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/13.jpg)
Summary of Policies (HCV)Summary of Policies (HCV)
![Page 14: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/14.jpg)
Human Immunodeficiency Human Immunodeficiency Virus Virus (HIV)(HIV)
• Retrovirus• First manifestation – early 1980s
• Human infection – early 20th Century (transmitted zoonotically to humans from primates in Africa)
• Mode of transmission:– Sexual contact– Blood to blood contact (blood transfusion,
needle stick injury (0.3%)
– Mother to child (20-45%)
![Page 15: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/15.jpg)
Summary of Policies (HIV)Summary of Policies (HIV)
![Page 16: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/16.jpg)
![Page 17: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/17.jpg)
Hepatitis Registry Hepatitis Registry • A central database for all ESRD patients
• To keep track of the serology & Hep B immunization status
• To prevent cross-infection amongst dialysis patients
• Registry created by Renal Dialysis CNC in December 2005
• Started collecting data from March 2005 to present
![Page 18: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/18.jpg)
The RegistryThe Registry……
• Each unit to update the registry as needed, i.e. new patients, serology/vaccination updates
• CNC to collate all data entered every 6 months• CNC to maintain the registry & alert units of
patients requiring follow-up (i.e. vaccination, serology, etc.)
• CNC to submit quarterly report to Director of Dialysis
• This initiative was awarded
![Page 19: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/19.jpg)
Performance IndicatorsPerformance Indicators1. Performance Indicator: Number of patients with
unknown serology at time of dialysis
Numerator: Number of patients with unknown serologyDenominator: Total number of acute dialysis (including late
referral i.e. <3 months)
2. Performance Indicator: Number of patients being vaccinated
Numerator: All patients having received even a single Hep B vaccination
Denominator: All patients (HD+PD) on maintenance dialysis with Hep BsAb <10 that require vaccination (excluding non-seroconvert patients)
![Page 20: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/20.jpg)
MultiMulti--Resistant Organism Resistant Organism (MRO)(MRO)
![Page 21: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/21.jpg)
Methycillin Resistant Methycillin Resistant Staphylococcus Aureus Staphylococcus Aureus (MRSA)(MRSA)
• Gram positive coccus • Found in wounds, intravascular lines
– Humans are the agreed reservoir – MRSA can colonise any favourable area on the body (nose, armpits, etc.)
• Transmission – Poor aseptic technique– Poor hand-washing technique– Spread primarily by close & direct contact– Sharing & multi-use of equipment without appropriate
disinfection/sterilisation– Misuse of antibiotics
![Page 22: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/22.jpg)
Summary of Policies (MRSA)Summary of Policies (MRSA)
![Page 23: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/23.jpg)
Vancomycin Resistant Vancomycin Resistant Enterococcus Enterococcus (VRE)(VRE)
• Enterococci• Susceptible people: immuno-compromised patients;
patients with IV lines
• Clinical infection requires treatment • VRE – first described in the UK in 1980s
– Multi-drug resistant– Colonized patients (majority) – Clinical infection – expensive and difficult to obtain
antibiotics may have to be administered
![Page 24: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/24.jpg)
Summary of Policies (VRE)Summary of Policies (VRE)
![Page 25: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/25.jpg)
The The Art Art of of
IsolationIsolation
![Page 26: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/26.jpg)
MRO MRO -- Transmission Transmission
• Environment (colonised)
• Hands of health care workers
• Spread from patient to patient
![Page 27: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/27.jpg)
![Page 28: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/28.jpg)
WHY ARE RENAL PATIENTS WHY ARE RENAL PATIENTS SUSCEPTIBLE to MRO?SUSCEPTIBLE to MRO?
• Lots of Vascaths, CAPD peritonitis, access cannulations
• Lots of infections -> lots of antibiotics• Lots of comorbidities
– age and diabetes• Dialyse in close proximity• Majority hospital based treatments• All use the same toilet• Interhospital transfers/ holiday patients
![Page 29: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/29.jpg)
Dialyser MembraneDialyser Membrane
![Page 30: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/30.jpg)
What is the risk of environmental What is the risk of environmental contamination by contamination by VREVRE--colonisedcolonised
patients who attend for patients who attend for Outpatient appointments, Outpatient appointments, radiological procedures & radiological procedures &
hemodialysis?hemodialysis?
![Page 31: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/31.jpg)
Melbourne VRE StudyMelbourne VRE Study• 15 mth surveillance program (April 1998 - July 1999)
• Three large university teaching hospitals– ARMC, MMC, Alfred Hospital– Strict infection control/isolation of colonised patients
• Units: – ICU (General, Road trauma, Cardiothoracic)– Renal– Haematology/Oncology– Transplant (Liver, Lung)
• 3458 patients; 4215 admissions; 8953 swabsProf. M. Lindsay Grayson, Infectious Diseases Department
Austin & Repatriation Medical Centre Department of Medicine, University of Melbourne
![Page 32: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/32.jpg)
![Page 33: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/33.jpg)
Contaminated sites duringContaminated sites during OutpatientOutpatient, radiology and H/D procedures, radiology and H/D procedures
• Chair arms 3/26 (12%)• Chair seat 13/26 (50%)• Couch/trolley 8/20 (40%)• Tap handles 1/36 (3%)• Door handles 1/36 (3%)• Stethoscope 1/36 (3%)• BP cuff/bulb 3/36 (8%)• Hemodialysis machine 1/16 (6%)• HCW gloved hands 3/26 (12%)• HCW unglove hand 1/36 (3%)• HCW gown 7/36 (19%)
Prof. M. Lindsay Grayson, Infectious Diseases Department Austin & Repatriation Medical Centre
Department of Medicine, University of Melbourne
![Page 34: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/34.jpg)
The Caring for Australian Renal Impairment The Caring for Australian Renal Impairment (CARI)(CARI)
Improving Patient Outcomes: Vascular Access Improving Patient Outcomes: Vascular Access ImplementationImplementation
Project 2008 Project 2008 -- 20092009
Implementation of CARI Guidelines on TimingImplementation of CARI Guidelines on Timingand Type of Vascular Access Formation inand Type of Vascular Access Formation in
Australasian CKD PatientsAustralasian CKD Patients
K. Polkinghorne, www.cari.org.auK. Polkinghorne, www.cari.org.au
![Page 35: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/35.jpg)
![Page 36: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/36.jpg)
Acute vascular access catheters for haemodialysis: Acute vascular access catheters for haemodialysis: Complications limiting technique survivalComplications limiting technique survival
} 55%
JEFFERYS, A.; CHOW, J; SURANYI, M. Nephrology 2003
![Page 37: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/37.jpg)
SUCCESSFUL CONTROL OF VRE SUCCESSFUL CONTROL OF VRE COLONISATIONCOLONISATION
• Publications attest to effectiveness of intervention including:– Active surveillance – Contact isolation – Cohorting – As well as altered antibiotic policies
• PREVENTION BETTER THAN TO HAVE TO DEAL WITH ACUTE EPIDEMIC CRISIS
![Page 38: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/38.jpg)
New VRE in Haemodialysis(Numerator = Number of NEW VRE cases in haemodialysis
Denominator = Total number of HD patients)
0%
2%
4%
6%
8%
10%
12%
14%
16%
18%
20%
3rd Qtr 2008 4th Qtr 2008 1st Qtr 2009 2nd Qtr 2009
Rat
e
0
10
20
30
40
50
60
Mar
-03
Jun-
03Se
p-03
Dec-0
3M
ar-0
4Ju
n-04
Sep-
04De
c-04
Mar
-05
Jun-
05Se
p-05
Dec-0
5M
ar-0
6Ju
n-06
Sep-
06De
c-06
Mar
-07
Jun-
07Se
p-07
Dec-0
7M
ar-0
8Ju
n-08
Sep-
08De
c-08
Mar
-09
Jun-
09
Cumulative VRE Data for InCumulative VRE Data for In--Centre and Isolation Centre and Isolation Haemodialysis Haemodialysis –– March 2003 to June 2009 March 2003 to June 2009
Liverpool HospitalLiverpool Hospital
![Page 39: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/39.jpg)
Isolation Isolation Rooms in the Rooms in the InIn--Centre Centre Haemodialysis Haemodialysis UnitUnit
![Page 40: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/40.jpg)
The VRE Isolation The VRE Isolation Haemodialysis Unit Haemodialysis Unit in Liverpool Hospitalin Liverpool Hospital
![Page 41: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/41.jpg)
A way forward for VREA way forward for VRE
![Page 42: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/42.jpg)
RecommendationsRecommendations-- HPA in London HPA in London (Health Protection Agency)(Health Protection Agency)
• Screening– Outbreaks (≥2 cases related time/place)– Selective media– Not necessarily enrichment
• Management– Only treat if infected– Check if sensitive to routine antibiotics– ?role of linezolid & quinupristin/dalfopristin
• Patients & staff– Carriage persists months to years– Clearance treatment not recommended– Don’t screen staff Cookson, et.at. 2006, Journal of Hospital Infection
![Page 43: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/43.jpg)
HPA recommendations Contrecommendations Cont’’dd• Risk assessment VRE outbreak• Patient by patient
– Extent of VRE– Incontinent [or Diarrhoea, colostomy]– Resistant to linezolid, etc.
• Hand hygiene– Soap fails, either antiseptic hand wash or alcoholic hand rub
• Isolation– Ideally, single rooms– Capacity exceeded, cohort
• Cleaning– Heavy contamination– No evidence any particular regimen superior– Hypochlorite or phenolic– Special attention dust-prone surfaces– Especially at termination of incident
• Inter-hospital transfer– Must notify recipient of VRE status– Not a risk for normal people in community
• Antibiotic stewardship– Fewer Glycopeptides & Cephalosporins– Vital to measure and feedback to prescribers– Sheet cost to budgets of prescribers
![Page 44: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/44.jpg)
Strategy in 2009 Strategy in 2009 -- Liverpool Infection Liverpool Infection Prevention Unit and the Renal Unit Prevention Unit and the Renal Unit
Implement 7 Pillars of MRO control– Administrative support– Education– Judicious use of antibiotics– MRO surveillance– Infection control precautions– Environmental measures– Decolonisation
Cookson, et.al., 2006
![Page 45: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/45.jpg)
Administrative supportAdministrative support• Health Department• Area Health Services• General Managers• Heads of Department• Expensive• Swabs• Gowns• Labour• Key communication to stakeholders• Ownership of the problem• KPIs
![Page 46: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/46.jpg)
EducationEducation
• All types of healthcare workers• All levels of seniority• Undergraduate programmes• Postgraduate programmes• Continuous• Mandatory• Feeding back KPIs
![Page 47: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/47.jpg)
![Page 48: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/48.jpg)
![Page 49: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/49.jpg)
Judicious use of antibioticsJudicious use of antibiotics• Selection of VRE increased by
Vancomycin related to need to Rx MRSA• Antibiotic policies• Restriction of certain antibiotics• Measurement of antibiotic use and feeding
this back to prescribers• Support by administration
![Page 50: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/50.jpg)
MRO surveillanceMRO surveillance• Role of screening• Must think through dealing with positives• Large numbers of colonised patients often found• Intensive screening programme with sensitive
method can find hundreds of carriers per infection
• Industrial concerns• Screen patients with high risk situations, e.g.
ICU, haematology• Need research
![Page 51: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/51.jpg)
Infection control precautionsInfection control precautions
• Isolate/cohort patients• Need to know who’s got the MROs• Flagging• Attention to hand hygiene• Gloves and Gowns• Physical barriers• Dealing with non-compliant HCWs
![Page 52: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/52.jpg)
Environmental measuresEnvironmental measures• Need to physically clean• Use disinfectants that will kill enterococci• Phenolics• Hypochlorite• ALL fomites• Toilets• Everything in rooms
![Page 53: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/53.jpg)
DecolonisationDecolonisation• Difficult but “do-able” with MRSA• Healthcare workers• Patients• Impossible with VRE and other superbug• Approx 30% may clear over time
– some excrete intermittently– some remain colonised for years– even low level colonisation is an infection
• Control risk if exposed to antibiotics• When colonisation recurs usually same strain,
i.e., not truly cleared
![Page 54: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/54.jpg)
VRE Clearance in Liverpool VRE Clearance in Liverpool HospitalHospital• Commenced late 2009• The preconditions for clearing:
– Undergoes Renal Dialysis– Is stable medically– Has no catheters other than a dialysis catheter– Has not have received antibiotics in the 3 months
prior to clearance– Does not have an acute wound, ulcer or tracheotomy
• Three neg. swabs to be taken one week apart• Dialyse out of the Isolation Unit
![Page 55: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/55.jpg)
Infection Control Issues andInfection Control Issues and ControversiesControversies
• VRE control measures don’t eradicate VRE
• Outbreak “control” usually means reduction of VRE to a lower level
• Unsuccessful control of outbreaks unlikely to be published
• Cost of control immense Royal Perth Hospital $AUD 2.7m
![Page 56: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/56.jpg)
Swine Flu (H1N1) vaccinationSwine Flu (H1N1) vaccination
The Australian Government is making Panvax® H1N1 vaccine available
![Page 57: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/57.jpg)
The priority groups for vaccinationThe priority groups for vaccination
• Front line health care and community care workers who have direct contact with patients
• People with underlying chronic medical conditions such as asthma, cancers, HIV, heart disease, diabetes and CKD
• People who are obese with a BMI over 35• Indigenous people and remote and isolated
communities with indigenous people• Children in special schools, initially only 10 years ad
over until child safety data is available• Pregnant woman• Parents and guardians of children aged 0-6 months
![Page 58: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/58.jpg)
ConclusionConclusion• No conclusive evidence of dialysis related transmission
in index patient• Isolation: does it make a difference?• Hepatitis registry: usefulness?• Implement 7 Pillars of MRO control
– Administrative support– Education– Judicious use of antibiotics– MRO surveillance– Infection control precautions– Environmental measures– Decolonisation
• Importance of Continuous auditing• Resource implications
![Page 59: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/59.jpg)
![Page 60: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/60.jpg)
Glycopeptide Glycopeptide Resistance in Resistance in S. aureusS. aureus
![Page 61: Prevention of Bacterial & Viral Cross- nfection in](https://reader033.vdocuments.mx/reader033/viewer/2022050520/6272a6c30d853d43e8648d61/html5/thumbnails/61.jpg)